Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03580655 · OUTCOME

Maximum Plasma Concentration (Cmax) of a Single Dose of Avapritinib

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · Source last updated 2026-04-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
ng/mL
Interval / dispersion
Full Range
Time frame
Day 1 of Cycle 1 (1 hour postdose) (28 days/cycle)

What was measured

Blood samples were collected at specified timepoints. Results reported as nanograms/milliliter (ng/mL).

Analysis population: Pharmacokinetic Population: all participants who received ≥1 dose of avapritinib and had had \>3 post-dose concentrations collected.

Groups in this outcome

Avapritinib

Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Avapritinib1

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Avapritinib191Not reported191191Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        191
        upper Limit
        191
        value
        191
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Blood samples were collected at specified timepoints. Results reported as nanograms/milliliter (ng/mL).
dispersion Type
Full Range
groups
  1. description
    Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.
    id
    OG000
    title
    Avapritinib
param Type
MEAN
population Description
Pharmacokinetic Population: all participants who received ≥1 dose of avapritinib and had had \>3 post-dose concentrations collected.
reporting Status
POSTED
time Frame
Day 1 of Cycle 1 (1 hour postdose) (28 days/cycle)
title
Maximum Plasma Concentration (Cmax) of a Single Dose of Avapritinib
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice